Prasugrel News and Research

RSS
FDA approves Effient (prasugrel) for heart attack in angioplasty patients

FDA approves Effient (prasugrel) for heart attack in angioplasty patients

FDA to review prasugrel for acute coronary syndromes

FDA to review prasugrel for acute coronary syndromes

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Big question over new blood-clot buster drug Prasugrel

Big question over new blood-clot buster drug Prasugrel

The goals of platelet inhibition in acute coronary syndromes

The goals of platelet inhibition in acute coronary syndromes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.